| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
|
Mol Cancer Ther
|
2010
|
5.24
|
|
2
|
Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages.
|
Arterioscler Thromb Vasc Biol
|
2006
|
4.07
|
|
3
|
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil.
|
Cancer Biol Ther
|
2010
|
2.68
|
|
4
|
Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
|
Mol Cancer Ther
|
2009
|
2.50
|
|
5
|
Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice.
|
J Biol Chem
|
2003
|
2.36
|
|
6
|
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
|
Int J Cancer
|
2004
|
1.52
|
|
7
|
MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
|
Mol Cancer Ther
|
2010
|
1.48
|
|
8
|
Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
|
Cancer Res
|
2006
|
1.32
|
|
9
|
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
|
Mol Cancer
|
2009
|
1.11
|
|
10
|
Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells.
|
Kidney Int
|
2003
|
1.04
|
|
11
|
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
|
Protein Sci
|
2007
|
1.01
|
|
12
|
Induction and down-regulation of Sox17 and its possible roles during the course of gastrointestinal tumorigenesis.
|
Gastroenterology
|
2009
|
0.99
|
|
13
|
Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis.
|
J Biol Chem
|
2005
|
0.98
|
|
14
|
Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus.
|
Proc Natl Acad Sci U S A
|
2006
|
0.95
|
|
15
|
Targeted disruption of H3 receptors results in changes in brain histamine tone leading to an obese phenotype.
|
J Clin Invest
|
2002
|
0.94
|
|
16
|
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation.
|
Curr Genomics
|
2008
|
0.91
|
|
17
|
Induction of prostaglandin E2 pathway promotes gastric hamartoma development with suppression of bone morphogenetic protein signaling.
|
Cancer Res
|
2009
|
0.91
|
|
18
|
Structures of the PKC-iota kinase domain in its ATP-bound and apo forms reveal defined structures of residues 533-551 in the C-terminal tail and their roles in ATP binding.
|
Acta Crystallogr D Biol Crystallogr
|
2010
|
0.89
|
|
19
|
Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines.
|
Mol Cancer
|
2009
|
0.88
|
|
20
|
Integrated genomic and pharmacological approaches to identify synthetic lethal genes as cancer therapeutic targets.
|
Curr Mol Med
|
2008
|
0.88
|
|
21
|
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
|
Mol Cancer Ther
|
2009
|
0.87
|
|
22
|
Expression levels of NF-Y target genes changed by CDKN1B correlate with clinical prognosis in multiple cancers.
|
Genomics
|
2009
|
0.87
|
|
23
|
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
|
Bioorg Med Chem Lett
|
2009
|
0.84
|
|
24
|
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.
|
Hum Genet
|
2010
|
0.82
|
|
25
|
Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice.
|
Neuropsychopharmacology
|
2013
|
0.82
|
|
26
|
Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.
|
Mol Cancer
|
2011
|
0.82
|
|
27
|
Mouse gastric tumor models with prostaglandin E2 pathway activation show similar gene expression profiles to intestinal-type human gastric cancer.
|
BMC Genomics
|
2009
|
0.80
|
|
28
|
Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders.
|
J Pharmacol Sci
|
2006
|
0.80
|
|
29
|
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
|
Invest New Drugs
|
2010
|
0.78
|
|
30
|
Simultaneous fluorometric measurement of histamine and tele-methylhistamine levels in rodent brain by high-performance liquid chromatography.
|
Anal Biochem
|
2004
|
0.77
|
|
31
|
Generation and characterization of highly constitutive active histamine H3 receptors.
|
J Pharmacol Exp Ther
|
2003
|
0.77
|
|
32
|
Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
|
Cell Cycle
|
2010
|
0.76
|
|
33
|
High-throughput assay for long chain fatty acyl-CoA elongase using homogeneous scintillation proximity format.
|
Assay Drug Dev Technol
|
2009
|
0.75
|
|
34
|
[Novel anti-cancer compounds targeting the cell cycle].
|
Nihon Yakurigaku Zasshi
|
2009
|
0.75
|
|
35
|
Impaired drinking response in histamine H3 receptor knockout mice following dehydration or angiotensin-II challenge.
|
Pharmacol Biochem Behav
|
2006
|
0.75
|